why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Drug FDA Status

Showing 30 of 139 result(s) (Page 3 of 14)
Drug Name: Enflonsia

Active Ingredient: clesrovimab-cfor

Approval Date: 2025-06-09

Description: To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season 
Drug Trials Snapshot

Drug Name: Tryptyr

Active Ingredient: acoltremon

Approval Date: 2025-05-28

Description: To treat the signs and symptoms of dry eye disease
Drug Trials Snapshot

Drug Name: Emrelis

Active Ingredient: telisotuzumab vedotin-tllv

Approval Date: 2025-05-14

Description: To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy 
Drug Trials Snapshot

Drug Name: Avmapki Fakzynja Co-Pack

Active Ingredient: avutometinib and defactinib

Approval Date: 2025-05-08

Description: To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
Drug Trials Snapshot

Drug Name: Imaavy

Active Ingredient: nipocalimab-aahu

Approval Date: 2025-04-29

Description: To treat generalized myasthenia gravis
Drug Trials Snapshot

Drug Name: penpulimab-kcqx

Active Ingredient: penpulimab-kcqx

Approval Date: 2025-04-23

Description: In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
Drug Trials Snapshot

Drug Name: Vanrafia

Active Ingredient: atrasentan

Approval Date: 2025-04-02

Description: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
Drug Trials Snapshot

Drug Name: Qfitlia

Active Ingredient: fitusiran

Approval Date: 2025-03-28

Description: To prevent or reduce the frequency of bleeding episodes in hemophilia A or B
Press Release
Drug Trials Snapshot

Drug Name: Blujepa

Active Ingredient: gepotidacin

Approval Date: 2025-03-25

Description: To treat uncomplicated urinary tract infections
Drug Trials Snapshot

Drug Name: Romvimza

Active Ingredient: vimseltinib

Approval Date: 2025-02-14

Description: To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity
Drug Trials Snapshot

300×250 Ad Slot